Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>Jyoti Nangalia, Anthony R. Green, Elli Papaemmanuil et al.|New England Journal of Medicine|2013Cited by 1.7k
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Siddharthan Chandran, Madhan Kolappan et al.|The Lancet Neurology|2012Cited by 606
A Comprehensive Microarray-Based DNA Methylation Study of 367 Hematological NeoplasmsJosé I. Martín‐Subero, Reiner Siebert, Ole Ammerpohl et al.|PLoS ONE|2009Cited by 137
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Siddharthan Chandran, Alan J. Thompson et al.|Trials|2011Cited by 119
Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCLJohn R. Davies, David W. Scott, Laura K. Hilton et al.|Blood Advances|2023Cited by 14